Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Phathom Pharmaceuticals, Inc.

NASDAQ: PHAT · Life Sciences · 5 alerts · CIK 1783183

Share price
$5.88Close, Nov 16
Market cap
$478M
Shares outstanding
81.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Phathom Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:46 PM ET 8-K
Clinical Trial Data

Phathom Pharmaceuticals Clinical Trial Data

Phathom Pharmaceuticals has initiated patient screening for pHalcon-NERD-302, a registrational Phase 3 study evaluating VOQUEZNA (vonoprazan) as an as-needed treatment for Non-Erosive Gastroesophageal Reflux Disease (NERD). The multicenter study aims to enroll approximately 500 adults across 80 U.S. sites, with topline results expected in the first quarter of 2028.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.